US panel says CRISPR priority determination by Patent Board needs a second look
In interference proceedings over CRISPR gene editing technology, the US Court of Appeals for the Federal Circuit today said the Patent Trial and Appeal Board must revisit their findings that The...To view the full article, register now.
Already a subscriber? Click here to view full article